Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
118
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Phase II Reactions: Methylation Reactions01:17

Phase II Reactions: Methylation Reactions

156
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
156

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Denosumab for Osteoporosis Treatment in Rheumatic Diseases: What Do We Know 15 Years Post Approval?

The Journal of rheumatology·2025
Same author

Expert Perspective: How, When, and Why to Potentially Stop Antiresorptive Drugs in Osteoporosis.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy.

Arthritis care & research·2024
Same author

"Burnout" Coupled with Workforce Shortages Spells Trouble: Innovative Solutions Are Essential for More Satisfying Rheumatology Practice.

Arthritis & rheumatology (Hoboken, N.J.)·2023
Same author

ACR Presidential Address: Rheumatologists-Folks You Can Trust.

Arthritis & rheumatology (Hoboken, N.J.)·2023
Same author

Serum Urate-Lowering Efficacy and Safety of Tigulixostat in Gout Patients With Hyperuricemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Trial.

Arthritis & rheumatology (Hoboken, N.J.)·2023

Related Experiment Video

Updated: Jun 12, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.5K

Methotrexate: Use in the Post Dobbs v. Jackson Era.

Edward M Huddleston1, Kenneth G Saag

  • 1From the Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham, Birmingham, Alabama.

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|September 26, 2024
PubMed
Summary

Methotrexate, a common drug for rheumatic diseases, has a complex history due to its use in abortions and teratogenic effects. Recent policy changes impact its use and rheumatologists' role in patient reproductive health.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Related Experiment Videos

Last Updated: Jun 12, 2025

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

2.5K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Area of Science:

  • Rheumatology
  • Pharmacology
  • Reproductive Health

Background:

  • Methotrexate is a cornerstone medication for various rheumatic diseases, including rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus.
  • Initially developed as chemotherapy, its efficacy in inflammatory conditions was recognized early on.
  • Methotrexate also has abortifacient properties and is a known teratogen, posing risks during pregnancy.

Purpose of the Study:

  • To examine the implications of recent US abortion policy changes on methotrexate use in rheumatology.
  • To explore the impact of the Dobbs v. Jackson Women's Health Organization ruling on provider and patient perspectives regarding methotrexate.
  • To highlight the evolving role of rheumatologists in addressing patients' sexual and reproductive health concerns.

Main Methods:

  • Review of recent literature and data concerning methotrexate use in the context of reproductive health and policy changes.
  • Analysis of provider perspectives and patient experiences post-Dobbs ruling.
  • Discussion of the intersection of rheumatology, teratogenicity, and abortion policy.

Main Results:

  • Recent data indicate that the Dobbs ruling has influenced both healthcare providers and patients concerning methotrexate.
  • The teratogenic nature and historical use of methotrexate for abortion complicate its prescription and management.
  • There is a growing need for rheumatologists to engage with patients on reproductive health matters.

Conclusions:

  • The current landscape of abortion policy in the US presents unique challenges for methotrexate's clinical application.
  • Rheumatologists are increasingly expected to navigate complex reproductive health discussions with patients on methotrexate.
  • Further research and guidelines are needed to support rheumatologists in managing methotrexate therapy amidst evolving reproductive rights.